PTC Therapeutics (PTCT)
(Real Time Quote from BATS)
$32.10 USD
+3.53 (12.36%)
Updated Apr 29, 2024 03:37 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTCT 32.10 +3.53(12.36%)
Will PTCT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTCT
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings
Other News for PTCT
PTC Therapeutics just upgraded at Morgan Stanley, here's why
PTC Therapeutics: A Balanced Hold Rating Amid Regulatory Challenges and Upcoming Milestones
RBC Capital Sticks to Their Hold Rating for PTC Therapeutics (PTCT)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Integer Holdings (ITGR), Resmed (RMD) and PTC Therapeutics (PTCT)
PTC Therapeutics price target raised by $1 at Citi, here's why